Navigation Links
Transplanted heart made more acceptable by daclizumab

Daclizumab has been found to reduce the risk of cellular rejection after a heart transplant// when used on top of standard immunosuppression.

The drug, a humanized monoclonal antibody, is directed against the interleukin-2 receptor, thereby inhibiting T-cell proliferation.

Patients who were taken into the Study were either given daclizumab or a placebo.

The primary endpoint was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within 6 months.

It has been reported 44.7% of patients in the placebo group reached the primary endpoint, versus just 35.6% in the daclizumab group–equivalent to a 25% relative risk reduction with the novel therapy Rejection was also less common with Daclizumab than Placebo. However, six patients receiving daclizumab died from infection when receiving concomitant cytolytic therapy compared with none in the placebo group.

When the negative aspect of daclizumab use is examined, researchers would not be willing to trade even a small increase in the risk of death from infection for a reduction in the risk of histologic rejection.


'"/>




Page: 1

Related medicine news :

1. Kidneys Can Be Transplanted From Animals Such As Pigs In Future
2. Transplanted Pancreatic Tissue Could Help Diabetics
3. MRI Can Monitor Transplanted Islets
4. White Blood Cells Can Both Hurt and Help Transplanted Kidneys
5. Study Reveals Effects of WBCs on Transplanted Kidney
6. HIV Positive Organs Transplanted
7. New Drug Mix to Extend Life of Transplanted Kidneys
8. Transplanted Pig Cells in Human Produce Insulin
9. Starvation in pregnant women can cause heart disease to their children
10. Individuals with sleep related breathing disorders more prone to heart disease
11. And now they say infections can cause heart disease!!!!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... Saint Francis Hospital ... years, and the efforts have paid off. Since implementation of these efforts, ... care to enhance perioperative patient experiences and reduce costly complications. Since implementation in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel ... for FCPX. , "This new layered style transition tool will keep a consistent flow ... CEO of Pixel Film Studios. , TranSweep is an all new layered style ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... industry leader in Blood Pressure products . , High blood pressure affects ... effects. Left untreated, high blood pressure can lead to heart disease, stroke, kidney ...
(Date:5/25/2016)... ... May 26, 2016 , ... The United States Food and Drug Administration ... both men and women. To date, the company is the first and only manufacturer ... adult who suffers with androgenetic alopecia. , “This new level of clearance substantiates ...
(Date:5/25/2016)... ... 25, 2016 , ... The Georgia State University College of Law new building ... Design Commission. , The annual award recognizes projects, programs, individuals and organizations that have ... of its physical heritage and the balance between the old and the new. , ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... today announced that Jeffrey H. Burbank , Chief ... of investor conferences. Where applicable, a webcast of the ...   ... Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
Breaking Medicine Technology: